Status:

Do Not Prescribe (DNP), Red

Decision Date:

February 2022

Comments

RED: Treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor. NHSE commissioned. (Decision date - February 2022)

TA1097: Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable (decision date October 2025)

DNP: NICE TA797 - Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal). NHSE commissioned. (Decision date - July 2022)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again